COVID-19 与皮肤科的免疫抑制治疗。
COVID-19 and immunosuppressive therapy in dermatology.
机构信息
Department of Dermatology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Department of Dermatology and Venereology, All India Institute of Medical Sciences, Patna, India.
出版信息
Dermatol Ther. 2020 Nov;33(6):e14140. doi: 10.1111/dth.14140. Epub 2020 Sep 3.
Abstract
Coronavirus 2019 (COVID 19) was first detected in December 2019 in China. It has become a pandemic. With concern about therapies that may decrease immunity and enhance the severity of an individual's COVID-19 infection, leading to a possibly fatal outcome, use of immunosuppressants has become an important concern. This work focuses on management of various skin diseases individuals lacking immunity to COVID-19 but requiring a systemic immunosuppressant, keeping in view the challenge of the COVID 19 pandemic and that our knowledge of this virus and its effects on the immune system are incomplete including knowledge as to an individual's immunity after COVID-19 infection.
摘要
2019 年冠状病毒（COVID-19）于 2019 年 12 月在中国首次发现。它已成为一种大流行病。由于担心可能会降低免疫力并加重个体 COVID-19 感染严重程度的治疗方法，导致可能致命的后果，因此免疫抑制剂的使用已成为一个重要关注点。这项工作重点关注管理各种皮肤疾病患者，这些患者对 COVID-19 缺乏免疫力，但需要全身性免疫抑制剂，鉴于 COVID-19 大流行的挑战以及我们对该病毒及其对免疫系统的影响的了解尚不完全，包括在 COVID-19 感染后个体免疫力的知识。
相似文献
1
COVID-19 and immunosuppressive therapy in dermatology.COVID-19 与皮肤科的免疫抑制治疗。
Dermatol Ther. 2020 Nov;33(6):e14140. doi: 10.1111/dth.14140. Epub 2020 Sep 3.
2
Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review.患有特定皮肤疾病且受 COVID-19 影响的患者：管理策略的经验有何说法？系统评价。
Dermatol Ther. 2020 Nov;33(6):e13867. doi: 10.1111/dth.13867. Epub 2020 Jul 7.
3
COVID-19 and immunosuppressants: An opinion pool of practicing dermatologists of India.2019冠状病毒病与免疫抑制剂：印度皮肤科执业医师观点汇总
Dermatol Ther. 2020 Nov;33(6):e14036. doi: 10.1111/dth.14036. Epub 2020 Aug 14.
4
Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.COVID-19 大流行中的皮肤表现和注意事项：系统评价。
Dermatol Ther. 2020 Nov;33(6):e13986. doi: 10.1111/dth.13986. Epub 2020 Aug 6.
5
Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic.在2019冠状病毒病大流行期间，对接受全身免疫抑制治疗或生物治疗或两者兼有的皮肤科患者进行管理的临床考量。
J Am Acad Dermatol. 2020 Jul;83(1):288-292. doi: 10.1016/j.jaad.2020.04.143. Epub 2020 May 4.
6
Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic.儿童炎症性皮肤病的全身免疫抑制治疗：基于专家共识的COVID-19大流行期间临床决策指南
Pediatr Dermatol. 2020 May;37(3):424-434. doi: 10.1111/pde.14202. Epub 2020 May 16.
7
Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.免疫抑制和免疫调节剂治疗大流行时期罕见或不常见的皮肤疾病。
Dermatol Ther. 2020 Sep;33(5):e13686. doi: 10.1111/dth.13686. Epub 2020 Jun 22.
8
Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS-CoV-2 (COVID-19) pandemic emergency: A quick review for a quick consultation.在 SARS-CoV-2（COVID-19）大流行期间治疗皮肤科疾病的全身性免疫生物学、免疫抑制剂和肿瘤药物：快速咨询的快速回顾。
Dermatol Ther. 2020 Sep;33(5):e13537. doi: 10.1111/dth.13537. Epub 2020 Jun 24.
9
Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.COVID-19 大流行期间皮肤科治疗药物的感染风险：基于证据的重新调整。
Int J Dermatol. 2020 Sep;59(9):1043-1056. doi: 10.1111/ijd.15028. Epub 2020 Jul 3.
10
The COVID-19 pandemic: implications for patients undergoing immunomodulating or immunosuppressive treatments in dermatology.2019冠状病毒病大流行：对皮肤科接受免疫调节或免疫抑制治疗患者的影响
Eur J Dermatol. 2020 Dec 1;30(6):757-758. doi: 10.1684/ejd.2020.3775.
引用本文的文献
1
Treatment Adherence in Dermatology During the COVID-19 Pandemic: A Review.COVID-19大流行期间皮肤科的治疗依从性：一项综述
Cureus. 2023 Jan 24;15(1):e34141. doi: 10.7759/cureus.34141. eCollection 2023 Jan.
2
COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.皮肤科免疫抑制患者的 COVID 疫苗推荐：大流行期间的经验教训。
J Cosmet Dermatol. 2022 Dec;21(12):6568-6573. doi: 10.1111/jocd.15448. Epub 2022 Dec 12.
3
Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study.COVID-19 大流行期间银屑病患者对系统性治疗的依从性：一项多中心研究。
J Cosmet Dermatol. 2022 Jan;21(1):39-47. doi: 10.1111/jocd.14610. Epub 2021 Nov 18.
4
Dermatologic comorbidities of the patients with severe COVID-19: A case-control study.重症 COVID-19 患者的皮肤科合并症：一项病例对照研究。
Dermatol Ther. 2021 Jan;34(1):e14731. doi: 10.1111/dth.14731. Epub 2021 Jan 10.
本文引用的文献
1
A dermatologist's perspective of the COVID-19 outbreak.皮肤科医生对新冠疫情的看法。
Dermatol Ther. 2020 Jul;33(4):e13538. doi: 10.1111/dth.13538. Epub 2020 Jun 23.
2
Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.2019冠状病毒病大流行期间自身免疫性大疱性疾病管理的专家建议。
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e302-e303. doi: 10.1111/jdv.16525. Epub 2020 Jun 4.
3
Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears.新冠疫情时代银屑病患者使用生物制剂：证据增多，恐惧减少。
J Dermatolog Treat. 2020 Jun;31(4):328-329. doi: 10.1080/09546634.2020.1757605. Epub 2020 Apr 27.
4
Treatment considerations for patients with pemphigus during the COVID-19 pandemic.COVID-19大流行期间天疱疮患者的治疗考量
J Am Acad Dermatol. 2020 Jun;82(6):e235-e236. doi: 10.1016/j.jaad.2020.04.005. Epub 2020 Apr 10.
5
The effect of quarantine and isolation for COVID-19 in general population and dermatologic treatments.新冠疫情期间隔离与检疫措施对普通人群的影响及皮肤科治疗
Dermatol Ther. 2020 Jul;33(4):e13398. doi: 10.1111/dth.13398. Epub 2020 Apr 25.
6
Priorities for global health community in COVID-19 pandemic.新冠疫情期间全球卫生界的优先事项。
Dermatol Ther. 2020 Jul;33(4):e13361. doi: 10.1111/dth.13361. Epub 2020 Apr 8.
7
Solidarity and transparency against the COVID-19 pandemic.团结与透明应对新冠疫情。
Dermatol Ther. 2020 Jul;33(4):e13359. doi: 10.1111/dth.13359. Epub 2020 Apr 13.
8
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis.欧洲特应性皮炎工作组关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染与特应性皮炎的声明。
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e241-e242. doi: 10.1111/jdv.16411.
9
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
10
Coronavirus infections and immune responses.冠状病毒感染与免疫应答。
J Med Virol. 2020 Apr;92(4):424-432. doi: 10.1002/jmv.25685. Epub 2020 Feb 7.
Zotero 插件